A dose or expansion path is unresolved
Clinical, safety, PK/PD, biomarker and regulatory considerations need one integrated position.
DECISION LAB / PROGRAMME SPRINT
One programme question. Ten business days.
A fixed, senior-led diagnostic that converts scattered evidence and competing views into a decision memo, risk map and owned 90-day plan.
VED working method
- 01Frame
- 02Challenge
- 03Commit
01
BEST USED WHEN
The next choice is consequential
A pivotal transition is approaching
The team must understand what evidence is sufficient, missing or still negotiable.
Global positions have drifted
US, EU and UK strategies need to be reconciled before execution or agency engagement.
A board or investor needs clarity
The decision, downside, dependencies and capital implications need independent challenge.
02
THE SPRINT
A disciplined ten-day sequence
- Day 0: agree the decision, boundary, stakeholders and source set
- Days 1–3: evidence review, contradiction map and assumption register
- Days 4–6: expert challenge, scenarios and regulatory precedent review
- Days 7–8: working session with the accountable team
- Days 9–10: final decision memo, risk register and 90-day action plan
03
OUTPUT
A decision package built to be used
The output is concise enough for governance and detailed enough for execution: recommended path, viable alternatives, evidence basis, critical assumptions, unresolved risks, regulatory implications, decision owners and immediate actions.
The sprint is successful when the team can act—not when the document is long.
Start with the constraint
What must your programme decide, prove or deliver next?
Share the situation, evidence and timing. We will propose the smallest credible first step.